NZ Keytruda Funding Knockback Sparks Drug Cost Row
This article was originally published in Scrip
The ongoing debate over the costs and benefits of new medicines for cancer and other diseases has been rekindled in New Zealand after the funding agency, Pharmac, said it would need more evidence of the benefits of Merck & Co's Keytruda (pembrolizumab) in advanced melanoma before it could recommend it for funding over other medicines with a better cost-effectiveness profile.
You may also be interested in...
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.
The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.